Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization
- 1 July 2008
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 90 (1), 231-233
- https://doi.org/10.1016/j.fertnstert.2007.06.030
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trialHuman Reproduction, 2006
- Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot studyReproductive BioMedicine Online, 2006
- Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilizationFertility and Sterility, 2005
- A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonistsHuman Reproduction, 2005
- GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized studyHuman Reproduction, 2005
- Ovarian hyperstimulation syndromeFertility and Sterility, 2003